{"nctId":"NCT00467870","briefTitle":"Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men","startDateStruct":{"date":"2006-03"},"conditions":["Hypogonadism","Primary Hypogonadism","Secondary Hypogonadism"],"count":531,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Testosterone Undecanoate 750 mg"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: Testosterone Undecanoate 1000 mg"]}],"interventions":[{"name":"Testosterone Undecanoate 750 mg","otherNames":[]},{"name":"Testosterone Undecanoate 1000 mg","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male with primary or secondary hypogonadism at least 18 years of age and for study part C2 weighs ≥143.3 lb (≥65 kg)\n* Morning screening serum testosterone concentration \\<300 ng/dL\n\nExclusion Criteria:\n\n* American Urological Association (AUA) Symptom Score ≥15 or significant prostatic symptoms\n* History of carcinoma, tumors or induration of the prostate or the male mammary gland including suspicion thereof\n* Screening serum prostate-specific antigen (PSA) level \\>4 ng/mL or hyperplasia of the prostate (size \\>75 cm3 as measured by transrectal ultrasonography)\n* Past or present liver tumors or acute or chronic hepatic disease with impairment of liver function; liver function tests (alanine aminotransferase \\[ALT\\], aspartate aminotransferase \\[AST\\]) exceeding 1.5 times upper limit of normal\n* History of deep vein thrombosis in the past 5 years or any history of cerebrovascular accident\n* Severe acne\n* Hypertension (systolic blood pressure \\>160 mm Hg and diastolic blood pressure \\>95 mm Hg) or coronary heart disease not stabilized by therapy as assessed by the investigator\n* Insulin-dependent diabetes mellitus or uncontrolled non-insulin-dependent diabetes mellitus; patients with diabetes are excluded if screening glycated hemoglobin (HbA1C) level is \\>9%\n* Use of any sex hormones within 28 days (for injectable testosterone preparations) or 7 days (for oral, gel, patch, etc, testosterone preparations) prior to screening visit and throughout the study (exclusive of administered study drug)\n* Use of steroidal anabolic drugs or supplements (eg, dehydroepiandrosterone \\[DHEA\\]) by any application method within the 28 days prior to first administration of study drug and throughout the study (exclusive of administrated study drug)\n* Medication with substances which might interfere with testosterone metabolism within 28 days before the first administration of study drug\n* History of sleep apnea Insulin-dependent diabetes mellitus\n* Use of steroidal anabolic drugs or supplements by any application method within the 28-days prior to the first administration of the study drug and throughout the study (exclusive of the administered study drug)","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Meeting Serum Total Testosterone Average Concentration Criteria for Responder During the 3rd Injection Interval in Part C","description":"Responders were participants with serum total testosterone average concentration (Cavg) between 300 and 1000 ng/dL derived from the 3rd injection intensive pharmacokinetic (IPK) interval.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Serum Total Testosterone Average Concentration During the 3rd Injection Interval in Part C","description":"Serum total testosterone Cavg derived from the 3rd injection IPK interval","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"494.9373","spread":"141.46351"}]}]}]},{"type":"PRIMARY","title":"Serum Total Testosterone Maximum Concentration During the 3rd Injection Interval in Part C","description":"Serum total testosterone maximum concentration (Cmax) derived from the 3rd injection IPK interval","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"890.583","spread":"345.1148"}]}]}]},{"type":"PRIMARY","title":"Serum Total Testosterone Concentration at the End of the Dosing Interval Following the 3rd Injection in Part C","description":"Serum total testosterone concentration at the end of the dosing interval (Ctrough) derived from the 3rd injection IPK interval","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"323.522","spread":"99.1081"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Meeting Serum Total Testosterone Average Concentration Criteria for Responder During the 4th Injection Interval in Part C","description":"Responders were participants with serum total testosterone Cavg between 300 and 1000 ng/dL derived from the 4th injection IPK interval.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Serum Total Testosterone Average Concentration During the 4th Injection Interval in Part C","description":"Serum total testosterone Cavg derived from the 4th injection IPK interval","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"514.2792","spread":"163.11476"}]}]}]},{"type":"PRIMARY","title":"Serum Total Testosterone Maximum Concentration During the 4th Injection Interval in Part C","description":"Serum total testosterone Cmax derived from the 4th injection IPK interval","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"837.648","spread":"412.0692"}]}]}]},{"type":"PRIMARY","title":"Serum Total Testosterone Concentration at the End of the Dosing Interval Following the 4th Injection in Part C","description":"Serum total testosterone Ctrough derived from the 4th injection IPK interval","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"342.800","spread":"106.9180"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Meeting Serum Total Testosterone Maximum Concentration Criteria for Success During the 2nd Injection Interval in Part C2","description":"Success was defined as having ≥85% of participants with Cmax ≤1500 ng/dL, ≤5% of participants with Cmax 1800-2500 ng/dL, and no participants with Cmax \\>2500 ng/dL.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Serum Total Testosterone Average Concentration During the 2nd Injection Interval in Part C2","description":"Serum total testosterone Cavg derived from the 2nd injection IPK interval","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"449.6455","spread":"157.00582"}]}]}]},{"type":"PRIMARY","title":"Serum Total Testosterone Maximum Concentration During the 2nd Injection Interval in Part C2","description":"Serum total testosterone Cmax derived from the 2nd injection IPK interval","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"689.002","spread":"266.9442"}]}]}]},{"type":"PRIMARY","title":"Serum Total Testosterone at the End of the Dosing Interval Following the 2nd Injection in Part C2","description":"Serum total testosterone Ctrough derived from the 2nd injection IPK interval","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"317.419","spread":"105.3124"}]}]}]},{"type":"SECONDARY","title":"Serum Total Testosterone Maximum Concentration in Part A","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"805.867","spread":"308.5417"},{"groupId":"OG001","value":"1023.591","spread":"394.3051"}]}]}]},{"type":"SECONDARY","title":"Serum Total Testosterone Maximum Concentration in Part B","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"986.364","spread":"330.4247"},{"groupId":"OG001","value":"1047.739","spread":"571.1648"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Meeting Serum Total Testosterone Maximum Concentration Criteria for Success During the 3rd Injection Interval in Part C","description":"Success is defined as having ≥85% of participants with Cmax ≤1500 ng/dL, ≤5% of participants with Cmax 1800-2500 ng/dL, and no participants with Cmax \\>2500 ng/dL.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With at Least 1 Serum Total Testosterone Level <300 ng/dL at Any Time During the 3rd Injection Interval in Part C","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Serum Total Testosterone Average Concentration ≥300 ng/dL During the 3rd Injection Interval in Part C","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First Serum Total Testosterone Concentration <300 ng/dL Following the 3rd Injection Interval in Part C","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.2","spread":"17.41"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Clinical Success During the 3rd Injection Interval in Part C","description":"Clinical success is defined as having both Cavg and Ctrough between 300 and 1000 ng/dL","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Serum Total Testosterone Maximum Concentration ≤1500, >1500 to <1800, 1800 to 2500, and >2500 ng/dL During the 3rd Injection Interval in Part C","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Meeting Serum Total Testosterone Maximum Concentration Criteria for Success During the 4th Injection Interval in Part C","description":"Success is defined as having ≥85% of participants with Cmax ≤1500 ng/dL, ≤5% of participants with Cmax 1800-2500 ng/dL, and no participants with Cmax \\>2500 ng/dL.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With at Least 1 Serum Total Testosterone Level <300 ng/dL at Any Time During the 4th Injection Interval in Part C","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Average Serum Total Testosterone Concentration ≥300 ng/dL During the 4th Injection Interval in Part C","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First Serum Total Testosterone Concentration <300 ng/dL Following the 4th Injection Interval in Part C","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.6","spread":"17.51"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Clinical Success During the 4th Injection Interval in Part C","description":"Clinical success is defined as having both Cavg and Ctrough between 300 and 1000 ng/dL","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Serum Total Testosterone Maximum Concentration ≤1500, >1500 to <1800, 1800 to 2500, and >2500 ng/dL During the 4th Injection Interval in Part C","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants by Collapsed Category for Each Parameter of the Male Patient Global Assessment (M-PGA) at Day 21 of the 3rd Injection Interval in Part C","description":"M-PGA is a 5-item self-report questionnaire to assess perception of change from pretreatment or baseline in hypogonadal symptoms including confidence/self-esteem, sexual performance, moods/behavior, overall feeling of well-being, and satisfaction with study treatment rated on a 7-point scale where items 1-4 were rated as 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse), 7 (very much worse) and item 5 was rated as 1 (very much satisfied), 2 (much satisfied), 3 (minimally satisfied), 4 (neither satisfied nor dissatisfied), 5 (minimally dissatisfied), 6 (much dissatisfied), 7 (very much dissatisfied). Collapsed ratings: Improved=Very much, much, or minimally improved; Worsened=Very much, much, or minimally worse; No change; Satisfied=Very much, much, or minimally satisfied; Not satisfied=Very much, much, or minimally dissatisfied; No opinion (neither satisfied nor dissatisfied).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Body Mass Index From Baseline to Week 24 in Part C","description":"Difference in Body Mass Index (BMI) from baseline to week 24 calculated from weight (kg) divided by height squared (m2)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.023","spread":"0.9543"}]}]}]},{"type":"SECONDARY","title":"Change in Weight From Baseline to Week 24 in Part C","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"3.009"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With at Least 1 Serum Total Testosterone Concentration >1000, >1100, >1250, and <300 or >1000 ng/dL During the 2nd Injection Interval in Part C2","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum Dihydrotestosterone Concentrations During the 2nd Injection Interval in Part C2","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"180.33","spread":"111.646"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"301.85","spread":"188.818"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"322.74","spread":"197.018"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"332.92","spread":"210.534"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"324.74","spread":"191.489"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"230.71","spread":"113.578"}]}]}]},{"type":"SECONDARY","title":"Serum Total Testosterone Concentrations in Part C2","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"197.629","spread":"75.8138"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"210.363","spread":"81.6797"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"254.669","spread":"112.7259"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"578.419","spread":"304.6675"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"606.484","spread":"266.4847"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"580.614","spread":"244.3727"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"545.236","spread":"234.5882"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"317.419","spread":"105.3124"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"316.215","spread":"126.1430"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"374.698","spread":"161.7627"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"375.797","spread":"136.5283"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Serum Total Testosterone Concentrations Outside the Normal Range in Part C2","description":"Serum total testosterone concentrations outside the normal range are categorized as \\<300 ng/dL (below lower limit of normal range) and \\>1000 ng/dL (above upper limit of normal range)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Trough Assessments of Serum Total Testosterone Concentrations in Part C2","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"197.629","spread":"75.8138"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"210.363","spread":"81.6797"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"254.669","spread":"112.7529"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"317.419","spread":"105.3124"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"316.215","spread":"126.1430"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"374.698","spread":"161.7627"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"375.797","spread":"136.5283"}]}]}]},{"type":"SECONDARY","title":"Serum Total Testosterone Maximum Concentration in Part C2","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"711.343","spread":"257.5643"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":38,"n":272},"commonTop":["Sinusitis","Upper respiratory tract infection","Prostatic specific antigen increased","Nasopharyngitis","Prostatitis"]}}}